Abstract:Recent studies showed that stereotactic ablative radiotherapy may provide survival benefit for cancer patients with a limited number of metastases lesions treated with curative intent. We hypothesized that stereotactic ablative radiotherapy is safe and effective in tumor control due to its ablative dose and high accuracy of irradiation. In this study we investigate the safety and efficacy of this treatment for patients with oligometastases from colorectal cancer (CRC). Forty-five histologically confirmed colorectal cancer patients were recruited from September 2017 to August 2019. The median age was 60 years and 12 patients were women. Each patient was treated with stereotactic ablative radiotherapy for one oligometastatic lesion unsuitable for resection or standard therapies. Among them 25 patients had lung metastasis, 12 had liver metastasis, 3 brain metastasis, 2 bone metastasis, 2 subcutaneously metastasis and 1 post peritoneal lymphatic nodes. Thirty-six (80%) patients had ≥1 systemic regimen before radiotherapy, and 17 (37.8%) patients had ≥2 regimens. The diameter of irradiated lesions ranges from 1 to 5.5cm. The prescribed doses were 32 to 40 Gy in 4 to 5 fractions to the brain lesions, 48 to 64 Gy in 6 to 8 fractions to the lung or liver lesions, 32 to 60 Gy in 4 to 10 fractions in other lesions, with modification according to the tolerance of the adjacent normal tissue. Biologically effective dose (BED) ranges from 57 to 132 Gy with a median of 86.4 Gy. The median follow-up period was 8 months (range, 2-21months). The 12-month and 18-month local control rates were 84.2% and 76.5%, respectively. In subgroups, the 12-month local control rates for BED ˂100 Gy and ≥100 Gy were 75% and 85% respectively. Local recurrence occurred in 5 patients (11.1%), among which 3 had KRAS mutant disease and 2 were of unknown KRAS status. Univariate analysis showed that there was no significant difference in local control rate based on BED value (˂100 Gy versus ≥100 Gy), KRAS status (mutant versus wild type) or metastatic tumor site (lung versus liver). The 6-month and 12-month PFS rate were 53.7% and 15.1% respectively and the median PFS was 7 months. There were no grade 3 or higher toxicities. Eight patients developed grade 2 acute toxicities including fatigue, cough and diarrhea; two patients developed grade 2 late toxicities including chronic cough and abdominal pain. This study showed that stereotactic ablative radiotherapy is well tolerated and effective for colorectal oligometastases. A prescription dose of BED ≥100 Gy should be considered if normal tissue constraints allow. Correlation of disease and treatment characteristics with local control needed to be investigated with larger cohort. Further homogenous cohort would better evaluate long term benefit of stereotactic ablative radiotherapy for patients with oligometastatic CRC.

Curative-intent Radiotherapy in Patients with Oligometastatic Lesions from Colorectal Cancer

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

[Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial].

Efficacy and Safety Outcomes of Using Stereotactic Ablative Radiotherapy for Oligometastatic Lesions from Colorectal Cancer

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients with Lung Oligometastases or Oligoprogression from Colorectal Cancer

Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Radiotherapy for Oligometastatic Tumor Improved the Prognosis of Patients with Non‐small Cell Lung Cancer (NSCLC)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.

110P Analysis for Stereotactic Body Radiotherapy (SBRT) Effect for Colorectal Liver Metastases

Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer

Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

A Phase II Prospective Study of Definitive Thoracic Concurrent Chemoradiation Followed by Consolidation Chemotherapy for Oligometastatic Non-Small Cell Lung Cancer.

Stereotactic Body Radiation Therapy for Oligometastatic Pulmonary Tumors from Cervical Cancer.

Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection with a Prediction Nomogram.

Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy (SBRT): a Single Institution's Experience.

Outcomes after Noncurative Locoregional Treatment in Patients with Unresectable Metastatic Colorectal Carcinoma.

Clinical Efficacy and Prognostic Factors of Stereotactic Body Radiotherapy for Pulmonary Oligometastases

Clinical Efficacy and Prognosis of Stereotactic Body Radiation Therapy for Pulmonary Oligometastases

Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: A case report